top of page
Search

Reimagining HIV Prevention: From Incrementalism to Community-Led Prevention at Scale

Nov 12
13 min read

Kenly Sikwese, Executive Director, AFROCAB Treatment Access Partnership


Imagine for a moment that HIV killed as quickly as Ebola, a disease that has killed, on average, around half of the people it infects (Ebola Disease, 2025). Would we accept fragmented prevention programmes, endless pilots and interventions that reach only a fraction of the people who could benefit? Would we tolerate delivery systems built around institutional convenience rather than people’s lives? We would not. We would deploy everything we have, everywhere it is needed, at once.


HIV’s slow progression has created a dangerous illusion of time. Treatment has transformed the prognosis of HIV, yet that success has not driven us to intensify prevention. Instead, we have grown comfortable with continued transmission. In 2025, 1.2 million people acquired HIV, more than 3,000 every single day, and new infections rose in 21 countries (Global HIV Response Falters as Reemergence Looms | UNAIDS, 2026). Every preventable infection represents a lifelong obligation to provide treatment and care, adding pressure to national health budgets that are already stretched. Prevention is therefore not simply a health intervention; it is a strategic investment in the long-term sustainability of health systems. At a time of extraordinary scientific progress, these figures demand an honest interrogation of how prevention is designed, financed, governed and delivered. We cannot end HIV by doing more of the same. If prevention is to succeed, we must close the chasm between scientific efficacy and population impact.


This complacency is now colliding with a financing crisis. International HIV financing fell by 18% in 2025, to its lowest level in nearly two decades, and in sub-Saharan Africa international aid had been paying for around 80% of prevention (Global HIV Response Falters as Reemergence Looms | UNAIDS, 2026). Prevention has been hit hardest. Across 62 countries, 38% fewer people received PrEP in 2025 than in 2024: 1.2 million people who lost access to protection in a single year (Agency, 2026). Business as usual is no longer an option.


When Ebola emerges, outbreak control brings together case finding, contact tracing, clinical care and community mobilisation. Responses may be slowed by delays and resource constraints, but the goal is unambiguous: contain transmission urgently. HIV demands the same urgency, even though its harm unfolds over years. Slower disease progression is no excuse for slower action.


The failure of incrementalism

HIV prevention has become incremental by design: a few populations, interventions, facilities and projects at a time. This may be administratively convenient, but the epidemic moves across relationships, communities and social networks simultaneously. Young people, women and girls, men, key populations and people living with HIV do not live separate lives. They share families, schools, workplaces, markets and communities. A young woman does not stop being young because a programme categorises her as a woman.


Yet prevention is organised around categories created by programmes and funding structures. Incrementalism is perpetuated by fragmented donor financing, narrowly defined programmes, institutional silos and rigid delivery systems that reward short-term project outputs over coordinated, sustained prevention at population scale. We need a response that connects effective interventions across the realities of people’s lives.


This is why we need a “bazooka” approach: everything that works, everywhere it can work, at the scale needed to change the course of the epidemic. Conventional combination prevention offers a menu; the bazooka approach demands the simultaneous, coordinated deployment of proven interventions at population scale, integrated across health services and communities, backed by sustained financing, meaningfully led by communities and accountable for results.


This does not mean doing everything, everywhere, on day one. With limited resources, start where HIV acquisition risk and unmet need are greatest, and let community preferences shape the choices offered. Match delivery to staff, supplies and referral capacity. Fund phased expansion against clear coverage targets and timelines. But phasing must be a route to scale, not another excuse for endless pilots.


The bazooka approach therefore needs a funded path from priority populations and places to broad coverage, matching the right intervention to different people and settings. What must end is the assumption that disconnected projects will somehow add up to the required scale without deliberate coordination, financing and community ownership.


Lessons from oral PrEP: lenacapavir must not repeat the same failures

Oral pre-exposure prophylaxis (PrEP) demonstrated both the power of biomedical HIV prevention and the limits of our delivery systems. About 3.9 million people received PrEP at least once in 2024, up from roughly 200,000 in 2017 (The Lancet HIV, 2024; UNAIDS, 2024). That is real progress, but it fell far short of the 2025 target of 21.2 million people (UNAIDS, 2025).


The problem was never simply the pill. It was the delivery architecture: dependence on health facilities, stigma, weak demand creation, fragmented financing, restrictive access pathways and limited community ownership. These structural barriers held back an otherwise highly effective intervention.


Twice-yearly injectable lenacapavir offers an unprecedented opportunity to overcome the burden of daily dosing and to fundamentally rethink how HIV prevention is delivered. In the PURPOSE 1 trial, not a single HIV infection occurred among the more than 2,000 adolescent girls and young women in South Africa and Uganda who received it (Bekker et al., 2024). WHO’s 2025 guidelines recommend lenacapavir as an additional prevention choice within combination HIV prevention and support the use of rapid diagnostic tests for initiating and continuing long-acting injectable PrEP, removing a major obstacle to delivery outside clinics (WHO, 2025b). Prices are falling too: generic lenacapavir is expected from 2027 at US$40 per person per year in 120 low- and middle-income countries (Miller, 2025).


But the product alone will not transform the epidemic. A revolutionary technology delivered through an outdated system will not produce revolutionary population-level impact.


Early rollout shows both the promise and the gap. Lenacapavir reached Eswatini and Zambia in late 2025, faster than any earlier HIV prevention innovation has reached low- and middle-income countries, and 100,000 people in nine African countries had started it by August 2026 (Prevention Breakthrough, 2026). Partners aim to reach 3 million people by 2028, yet UNAIDS estimates that 20 million people need antiretroviral-based prevention (Press Statement | UNAIDS, 2026). Speed of introduction is not the same as scale.


Unless we dismantle restrictive delivery systems, decentralise access, accelerate regulatory approvals, invest in community-led demand creation and mobilise sustainable financing for rapid scale-up, lenacapavir risks repeating the missed opportunities of oral PrEP.

The central question, then, is not simply how quickly countries can introduce lenacapavir, but whether they are prepared to transform the architecture through which prevention is delivered.


Will we surround two injections a year with the same fragmented financing, restrictive pathways and limited community ownership? Or will we redesign prevention around the people who need it and want it?


The lesson from oral PrEP is clear: biomedical innovation must be matched by delivery innovation. That means differentiated service delivery, meaningful community leadership, sustained demand creation, integrated prevention services and financing that enables equitable access at scale. Without these changes, lenacapavir may become another scientific breakthrough whose population-level impact falls short of its promise.


A monthly pill could redefine access

Merck’s investigational once-monthly oral PrEP, alimatravir (MK-8527), now in Phase 3 trials, could redefine HIV prevention again (MERCK, 2026). It could offer discreet, self-administered protection, subject to evidence on its onset of protection, safety and effectiveness. If alimatravir is proven safe and effective and approved by regulators, twelve pills a year, rather than a daily pill or a provider-administered injection, could be transformative for people who prefer oral prevention. Encouragingly, Merck has already granted royalty-free voluntary licences to seven generic manufacturers, three of them in sub-Saharan Africa, before Phase 3 enrolment is complete. But its impact will depend on evidence, regulatory approval and whether we break with conventional access models.


We should aspire to make effective HIV prevention as ubiquitous and convenient as Coca-Cola: available wherever people live, work, travel and socialise, through the settings people tell us they want to use, including clinics, pharmacies, community outlets, workplaces and general retail outlets.


If we develop effective technology and then make people navigate a maze to obtain it, we will have failed before we begin.


The wider research pipeline, including broadly neutralising antibodies, implants, multipurpose prevention products and vaccines, could expand choice further (Torres-Rueda et al., 2023). We should build delivery systems now, rather than wait for each technology to arrive before deciding how people will access it.


Break the fences around prevention

We cannot claim to want broader access while erecting fences around it. Who decides who can deliver prevention, where it can be delivered and which communities are trusted? Who controls the resources, and where are the people who will use these interventions when those decisions are made?


Responsible oversight matters, but it must be distinguished from unnecessary gatekeeping. Every unnecessary barrier reduces reach.


Nearly two decades ago, while training in HIV testing and counselling, I had to learn basic phlebotomy. At the time, drawing blood was the preserve of health workers. Yet the HIV response progressively trained lay counsellors and community adherence supporters to do it safely. That experience should inform injectable prevention. Injections require proper training, supervision, quality assurance and regulation. They do not require every dose to be given inside a hospital or conventional clinic.


WHO’s 2025 lenacapavir guidelines call for community participation in designing, implementing and monitoring programmes, support for community-led organisations and expanded community-based services (WHO, 2025). We should implement regulated decentralisation and task sharing through trained providers, pharmacies, mobile services, peer-led programmes, youth-friendly spaces and other accessible settings. Delivery should follow people, not the other way round.


Convenience must be designed into services from the beginning. A delivery model that looks efficient on paper may still fail someone who cannot leave work, afford transport, or enter a facility without fear of being recognised or stigmatised. Community input can expose those barriers before they become reasons for poor uptake, but only if listening changes actual service design: opening hours, locations and the choices people are offered.


Put communities back in the saddle

The HIV response was transformed when communities became political actors. They confronted pharmaceutical companies and governments, demanding treatment, affordable medicines, dignity and the right to be heard. Prevention needs that same spirit.


Today, communities are invited to meetings, asked for feedback and called upon to validate strategies. But consultation is not leadership. Putting communities back in the saddle means sharing power: giving communities direct access to financing, decision-making authority over programme priorities, design and delivery, and meaningful roles in governance, implementation and accountability for results.


This matters more than ever, because community-led organisations have been among the first casualties of the funding crisis. A 2026 study across 47 countries found that community-led services for prevention medicines and HIV care had fallen by half, and services for sex workers and for gay men and other men who have sex with men by more than 80% (UNAIDS, 2026c).


Communities must also have the resources to generate demand, monitor quality, produce data and influence policy.


Community leadership should not be an ornamental component of HIV programmes. It should be part of the operating system.


Community leaders understand stigma, fear, misinformation and why people do not use services. Use that intelligence. Pay for it. And hold communities accountable for results alongside everyone else.


Urgency without stigma

Prevention messaging can become so cautious that urgency disappears. Messaging must be driven by the communities we seek to reach. It must draw on people’s lived experience, perceptions of risk and social realities to deliver bold, culturally relevant and a stigma-free communication that inspires action, creates demand and connects people to accessible prevention services. We should never shame anyone for acquiring HIV, but neither should we be afraid to say that HIV prevention still matters. Hard-hitting communication must provide accurate information and practical ways to stay protected, while respecting the dignity of people living with HIV. Young people deserve the truth, alongside accessible services, meaningful choices and the power to act. Urgency loses credibility when we tell people to prevent HIV but make prevention difficult to access.


Keep U=U at the centre

Undetectable equals Untransmittable (U=U) is still one of the most powerful prevention messages we have. People living with HIV who achieve and maintain an undetectable viral load do not transmit HIV sexually (Rodger et al., 2019; WHO, 2023). Treatment access and sustained viral suppression are central to prevention. Yet U=U has not always received the prominence it deserves.  Early diagnosis, prompt treatment initiation and retention in care make viral suppression possible. People living with HIV are central actors in ending transmission and must be recognised as such. U=U must become an integral pillar of combination prevention, linking uninterrupted treatment, sustained viral suppression and community-led services.


U=U should be heard in clinics, schools, universities, community campaigns, on radio and across social media. Treatment success gives us a powerful reason to strengthen both treatment access and prevention.


The choices we make now will determine whether new prevention technologies narrow existing inequalities or reproduce them. If access depends on the same barriers, the same underserved people will remain excluded. We should judge readiness by whether people can obtain and continue the prevention they choose, with the support they need. Innovation must reach beyond the product itself into financing, regulation, service delivery and community decision-making: from pipeline to people.


A prevention compact built for scale

A new prevention compact must move beyond declarations of intent to concrete, time-bound commitments, with governments, funders, regulators, manufacturers, health providers and communities sharing responsibility for transforming HIV prevention into a coordinated, adequately financed and accountable response capable of population-level impact. The 2030 targets adopted by UN Member States in June 2026, including access to antiretroviral-based prevention for 20 million people, give it a clear yardstick (UNAIDS, 2026). The compact should rest on seven commitments:


First, expand access. When an intervention is proven safe and effective and has been approved, eliminate unnecessary regulatory, institutional and administrative barriers that delay or restrict access, particularly for underserved populations.


Second, liberalise delivery. Enable appropriately trained and supervised community providers and other non-traditional health actors to deliver prevention through pharmacies, mobile services, workplaces, community outlets and other accessible settings, supported by quality assurance and reliable referral systems.


Third, finance community leadership. Move beyond tokenistic consultation by providing community-led organisations with direct, sustained financing, genuine decision-making authority and meaningful roles in programme design, implementation, governance and accountability.


Fourth, make prevention choice real. Ensure equitable access to a comprehensive range of proven prevention options, including daily oral and long-acting PrEP, condoms, testing, U=U, voluntary medical male circumcision and harm reduction, alongside integrated STI and sexual and reproductive health services. Introduce emerging technologies as evidence supports their use and regulatory approvals are secured.


Fifth, mainstream prevention across health care. Make HIV prevention a routine responsibility across health services and service delivery points,  dismantling institutional silos so that no prevention opportunity is missed wherever people interact with the health system.


Sixth, reform financing and fund scale. Replace fragmented, short-term project financing and endless pilots with coordinated, sustained investment tied to clearly defined national coverage targets, timelines and measurable outcomes. Domestic resources already provide around 60% of HIV funding in low- and middle-income countries (IAS, 2026). Governments must build on that, and development partners must prioritise financing arrangements that enable rapid expansion, community-led delivery and long-term sustainability.


Seventh, establish accountability for results. Governments, funders, implementers and communities must commit to transparent, time-bound targets for equitable access, uptake, continuity and population coverage, supported by community-led monitoring and independent assessment. Success must be judged not by the number of meetings, projects, training sessions or commodities distributed, but by sustained protection and falling numbers of new HIV infections.


Delivering this compact will require realigning institutional priorities, financing, regulation and decision-making power to translate scientific breakthroughs into measurable population impact.


The test of leadership

We have spent four decades learning how to manage HIV. Now we must demonstrate that we have learned how to prevent it at scale. That requires leaders prepared to challenge professional boundaries, funding structures and institutional interests when they stand between effective prevention and the people who need it. The test is whether governments, funders and institutions have the political courage to dismantle restrictive policies, redirect resources towards community-led prevention and deliver measurable reductions in new HIV infections.


Leadership means removing barriers, financing delivery, sharing control with communities and accepting accountability for results. We cannot celebrate scientific breakthroughs while failing to translate them into population impact. We cannot call communities essential while withholding the resources and authority they need to lead. And we cannot expect young people to embrace prevention that is difficult to access. The next phase must be ambitious, evidence-based, accountable and people-centred. Its scale must match the epidemic we claim we want to end.


Reimagine prevention. Break the fences. Put communities back in the saddle. And deliver prevention at the scale the epidemic demands. If HIV killed as quickly as Ebola, we would already be doing all of this. The slowness of the virus can no longer excuse the slowness of our response.


Download artile below




REFERENCES:


1.     Agency, R. (2026, June 12). Funding cuts drive sharp drop in HIV prevention, UNAids says. TimesLIVE. https://www.timeslive.co.za/news/world/2026-06-12-funding-cuts-drive-sharp-drop-in-hiv-prevention-unaids-says/


2.     Bekker, L.-G., Das, M., Karim, Q. A., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., Kiwanuka, N., Kotze, P., Lebina, L., Louw, C. E., Malahleha, M., Manentsa, M., Mansoor, L. E., Moodley, D., Naicker, V., … Kiweewa, F. M. (2024). Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. New England Journal of Medicine, 391(13), 1179–1192. https://doi.org/10.1056/NEJMoa2407001




5.     IAS. (2026). Funding for the global HIV response plunged in 2025, with devastating consequences | International AIDS Society (IAS). https://www.iasociety.org/news-release/funding-global-hiv-response-plunged-2025-devastating-consequences


6.     MERCK. (2026). Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development. Merck.Com. https://www.merck.com/news/merck-announces-initial-access-plans-for-alimatravir-an-investigational-once-monthly-oral-hiv-pre-exposure-prophylaxis-in-phase-3-development/


7.     Miller, S. (2025, September 24). Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs. Clinton Health Access Initiative. https://www.clintonhealthaccess.org/news/unitaid-chai-wits-rhi-dr-reddys-lenacapavir-agreement/


8.     Press Statement | UNAIDS. (2026). https://www.unaids.org/en/story-type/press-statement


9.     Prevention Breakthrough: A Historic HIV Innovation Delivered at Unprecedented Speed. (2026, September 16). The Global Fund to Fight AIDS, Tuberculosis and Malaria. https://www.theglobalfund.org/en/stories/2026/2026-09-16-prevention-breakthrough-historic-hiv-innovation-delivered-unprecedented-speed/


10. Rodger, A. J., Cambiano, V., Bruun, T., Vernazza, P., Collins, S., Degen, O., Corbelli, G. M., Estrada, V., Geretti, A. M., Beloukas, A., Raben, D., Coll, P., Antinori, A., Nwokolo, N., Rieger, A., Prins, J. M., Blaxhult, A., Weber, R., Eeden, A. V., … Janeiro, N. (2019). Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study. The Lancet, 393(10189), 2428–2438. https://doi.org/10.1016/S0140-6736(19)30418-0


11. The Lancet HIV, null. (2024). A game-changer for PrEP if access is adequate. The Lancet. HIV, 11(9), e567. https://doi.org/10.1016/S2352-3018(24)00217-0


12. Torres-Rueda, S., Terris-Prestholt, F., Gafos, M., Indravudh, P. P., Giddings, R., Bozzani, F., Quaife, M., Ghazaryan, L., Mann, C., Osborne, C., Kavanagh, M., Godfrey-Faussett, P., Medley, G., & Malhotra, S. (2023). Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward. PharmacoEconomics, 41(7), 787–802. https://doi.org/10.1007/s40273-022-01231-w


13. UNAIDS. (2024). The Urgency of Now: AIDS at a Crossroads. Joint United Nations Programme on HIV/AIDS.


14. UNAIDS. (2025). AIDS, crisis and the power to transform: UNAIDS Global AIDS Update 2025. Joint United Nations Programme on HIV/AIDS.


15. UNAIDS. (2026a). The 2026 UN Political Declaration on HIV/AIDS: Accelerating progress towards ending AIDS as a public health threat | UNAIDS. https://www.unaids.org/en/resources/presscentre/featurestories/2026/june/20260629_HLM_PD


16. UNAIDS. (2026b). UNAIDS: FACT SHEET 2026. Joint United Nations Programme on HIV/AIDS. https://www.unaids.org/sites/default/files/2026-07/2026_UNAIDS_Global_HIV_Factsheet_en.pdf


17. UNAIDS. (2026c). UNAIDS Special report for the 26th International AIDS Conference: United to end AIDS (pp. 18, Chapter 2). Joint United Nations Programme on HIV/AIDS.


18. WHO. (2023). The role of HIV viral suppression in improving individual health and reducing transmission. https://www.who.int/publications/i/item/9789240055179


19. WHO. (2025a). Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. https://www.who.int/publications/i/item/9789240111608


20. WHO. (2025b). WHO recommends injectable lenacapavir for HIV prevention. World Health Organization. https://www.who.int/news/item/14-07-2025-who-recommends-injectable-lenacapavir-for-hiv-prevention

 

 

 
 
 

Comments


bottom of page